Medicis won't raise$2.8B Inamed offer

by admin |

Medicis has chosen not to pursue a buyout of Inamed after offering $2.8 billion for the company in March 2005. Botox-maker Allergan trumped Medicis' by offering to buy Inamed for a substantially higher price--$3.2 billion. Inamed will pay Medicis a $90 million termination fee.

- read this AP report

Suggested Articles

Publicly traded hotel companies beholden to Wall Street
Biotech

Struggling Tocagen becomes Nasdaq on-ramp for Forte Bio

Out of options, Tocagen will become Forte Biosciences’ route to the public markets through an all-stock reverse merger.

by Amirah Al Idrus
Pen on a business contract
Biotech

Effector co-founder leaves to take up CSO post at Turning Point

Reich co-founded Effector and served as its SVP of research but has moved on to take up the CSO position at Turning Point Therapeutics.

by Nick Paul Taylor
BioMarin
Biotech

BioMarin gene therapy won't need an AdComm

BioMarin’s hemophilia A drug has been set an Aug. 21 PDUFA date as the California biotech looks to gain a speedy approval.

by Ben Adams